Intracellular delivery of serum-derived hepatitis C virus

Takasuke Fukuhara, Hideki Tani, Mai Shiokawa, Yukinori Goto, Takayuki Abe, Akinobu Taketomi, Ken Shirabe, Yoshihiko Maehara, Yoshiharu Matsuura

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


A robust and reliable cell culture system for serum-derived HCV (HCVser) has not been established yet because of the presence of neutralizing antibody and tropism for infection. To overcome this obstacle, we employed a lipid-mediated protein intracellular delivery reagent (PIDR) that permits internalization of proteins into cells. Although entry of HCVcc was not enhanced by the treatment with PIDR, entry of HCVser into hepatoma cell lines (Huh7 and HepG2) and immortalized primary hepatocytes (Hc and HuS/E2) was significantly enhanced by the PIDR treatment. The entry of HCVser into Huh7 cells in the presence of PIDR was resistant to the neutralization by an anti-hCD81 antibody, suggesting that PIDR is capable of internalizing HCVser in a receptor-independent manner. Interestingly, the PIDR-mediated entry of HCVser and HCVcc was enhanced by the addition of sera from chronic hepatitis C patients but not from healthy donors. In addition, neutralization of HCVcc infection by anti-E2 antibody was canceled by the treatment with PIDR. In conclusion, the PIDR is a valuable tool to get over the obstacle of neutralizing antibodies to internalize HCV into cells and might be useful for the establishment of in vitro propagation HCVser.

Original languageEnglish
Pages (from-to)405-412
Number of pages8
JournalMicrobes and Infection
Issue number4
Publication statusPublished - Apr 2011

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Intracellular delivery of serum-derived hepatitis C virus'. Together they form a unique fingerprint.

Cite this